Patrys Ltd (ASX:PAB)'s Dr James Campbell says they've established a high-yielding, stable cell line ahead of schedule to support production of its PAT-DX3 drug candidate. He says there's potential for PAT-DX3 to be used as both a therapeutic and targeting agent in antibody drug conjugates (ADCs), which opens up several potential development and partnering opportunities.
Patrys identifies stable cell line for production of PAT-DX3
